Work

Evaluating intermittent schedules of the oral RAF-MEK inhibitor CH5126766 in patients with RAS/RAF-mutated solid tumours and multiple myeloma: a single-centre, phase 1 trial.

FWCI:
Cites:
Cited by:
Related to: 10